Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females aged 18 to 70 years, inclusive, at screening~* Documented chronic genotype 1, 2, or 3 HCV infection~* No previous treatment with HCV antiviral mediations~* Body mass index (BMI) of greater than 18 kg/m2, but not exceeding 36 kg/m2.~* Liver biopsy obtained within 3 years prior to the Day 1 visit, with a fibrosis classification of non-cirrhotic as judged by a local pathologist~* Willing to refrain from beginning any new exercise regimens during the first 3 months of the study~* Fasting blood glucose ≤ 300 mg/dl and/or glycosylated hemoglobin (HbA1c) ≤ 8~* History of hypertension only if managed effectively on a stable regimen of two or fewer antihypertensives for at least three (3) months prior to screening~Exclusion Criteria:~* Females who were breastfeeding~* Males and females of reproductive potential who are unwilling to use an effective, protocol-specified method(s) of contraception during the study~* Positive test at Screening for HBsAg, anti-HBc IgM Ab, or anti-HIV Ab.~* History of any other clinically significant chronic liver disease~* Treatment with herbal/natural remedies with antiviral activity within 30 days prior to baseline.~* Significant history of immunologically mediated disease, cardiac or pulmonary disease, seizure disorder or anticonvulsant use~* History of ascites, variceal hemorrhage, hepatic encephalopathy, or conditions consistent with decompensated liver disease~* Use of medications associated with QT prolongation within 30 days prior to dosing~* Screening electrocardiogram (ECG) QTc value greater than 450 ms and/or clinically significant ECG findings~* Personal or family history of Torsade de pointes.~* Positive results for drugs of abuse test at screening~* Abnormal hematological and biochemical parameters, including alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 5 times the upper limit of the normal range (ULN)~* History of major organ transplantation with an existing functional graft~* History of uncontrolled thyroid disease or abnormal thyroid-stimulating hormone (TSH) levels at screening~* Clinically significant drug allergy to nucleoside/nucleotide analogs~* History or current evidence of psychiatric illness, immunologic disorder, pulmonary, cardiac disease, seizure disorder, cancer or history of malignancy that in the opinion of the investigator makes the patient unsuitable for the study~* History of systemic antineoplastic or immunomodulatory treatment within 6 months prior to dosing, or the expectation of such treatment during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Sofosbuvir 200 mg (Genotype 1) (Type: EXPERIMENTAL): Participants with genotype 1 HCV infection were randomized to receive sofosbuvir 200 mg (2 x 100 mg tablets)+placebo to match sofosbuvir (2 tablets)+PEG+RBV for 12 weeks followed by PEG+RBV for up to an additional 36 weeks.
- Sofosbuvir 400 mg (Genotype 1) (Type: EXPERIMENTAL): Participants with genotype 1 HCV infection were randomized to receive sofosbuvir 400 mg (4 x 100 mg tablets)+PEG+RBV for 12 weeks followed by PEG+RBV for up to an additional 36 weeks.
- Placebo (Genotype 1) (Type: ACTIVE_COMPARATOR): Participants with genotype 1 HCV infection were randomized to receive placebo to match sofosbuvir (4 tablets)+PEG+RBV for 12 weeks followed by PEG+RBV for up to an additional 36 weeks.
- Sofosbuvir 400 mg (Genotype 2/3) (Type: EXPERIMENTAL): Participants with genotype 2 or 3 HCV infection received sofosbuvir 400 mg (4 x 100 mg tablets)+PEG+RBV for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).